Many young adult survivors of childhood hematologic cancer do not have comprehensive survivorship care summaries or believe they need one.

Mild CMV reactivation was associated with beneficial effects, while severe cases required treatment, which increased the risk of toxicity and infections.

Cancer patients without health insurance have not derived the same benefits from the introduction of ICIs as patients with private insurance.

Lurbinectedin plus atezolizumab significantly reduced the risk of disease progression or death by 46% compared with atezolizumab alone.

Omitting carboplatin could be an efficacious de-escalated neoadjuvant strategy in the presence of dual HER2 blockade for patients with HER2-positive early breast cancer,” said Kun Wang, MD, PhD.